scholarly journals Estimasi Nilai Years Lived with Disability (YLD) Terhadap Penyakit Respirasi Akibat Rokok di Indonesia

2021 ◽  
Vol 2 (1) ◽  
pp. 135-140
Author(s):  
Nurul Faizah
Keyword(s):  
Relative Risk ◽  
Respiratory Disease ◽  
Respiratory Diseases ◽  
Real Data ◽  
Attributable Fraction ◽  
Chronic Obstructive ◽  
Social Security Administration ◽  
Number Of Patients ◽  
Years Lived With Disability ◽  
The Impact

ABSTRAK Merokok merupakan salah satu kekhawatiran terbesar yang dihadapi dunia kesehatan karena menyebabkan lebih dari 5 juta orang meninggal dalam setahun. Penelitian ini bertujuan untuk mengetahui dampak rokok terhadap penyakit respirasi di Indonesia menggunakan Years Lived with Disability (YLD). Penelitian ini merupakan studi epidemiologi dengan perspektif govermental. Pemilihan jenis penyakit respirasi akibat rokok diperoleh berdasarkan nilai relative risk >1 dan ketersediaan data pada Badan Penyelenggara Jaminan Sosial (BPJS) Kesehatan. Proporsi kontribusi rokok terhadap penyakit-penyakit diestimasi dengan mengaplikasikan smoking attributable fraction (SAF) yang didapatkan dengan mengalikan hasil prevalensi merokok di Indonesia dengan relative risk. Selanjutnya estimasi YLD penyakit respirasi akibat rokok dihitung berdasarkan data riil jumlah pasien yang diperoleh dari database BPJS tingkat nasional. Nilai YLD tertinggi pada penyakit respirasi akibat rokok dalam penelitian ini adalah penyakit paru obstruksi kronis, disusul bronkitis, emfisema dan pneumonia. Kata kunci : rokok, respirasi, YLD, BPJS ABSTRACT Smoking is one of the biggest concerns facing the health world, because it causes more than 5 million people to die in a year. This study aims to determine the impact of smoking on respiratory diseases in Indonesia using Years Lived with Disability (YLD). This research is an epidemiological study with a govermental perspective. Selection of types of respiratory diseases due to smoking is obtained based on the value of relative risk> 1 and the availability of data on the Health Social Security Administration (BPJS). The proportion of the contribution of smoking to diseases is estimated by applying the smoking attributable fraction (SAF) which is obtained by multiplying the results of smoking prevalence in Indonesia with the relative risk. Furthermore, the YLD estimate of smoking-induced respiratory disease is calculated based on real data on the number of patients obtained from the national BPJS database. The highest YLD value in smoking-induced respiratory disease in this study was chronic obstructive pulmonary disease, followed by bronchitis, emphysema and pneumonia. Keywords: smoking, respiration, YLD, BPJS  

Hazards for Construction Workers

2017 ◽  
Author(s):  
Gavin H. West ◽  
Laura S. Welch
Keyword(s):  
Heavy Metals ◽  
Prevention And Control ◽  
Respiratory Diseases ◽  
Noise Exposure ◽  
Engineered Nanomaterials ◽  
Construction Workers ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
And Control ◽  
The Impact

This chapter describes the hazards for construction workers, with a particular focus on injuries as well as exposures to hazardous chemicals and dusts. A section describes hazardous exposures to lead and other heavy metals. Another section describes noise exposure. The impact of musculoskeletal disorders among construction workers is then discussed. A section on respiratory diseases focuses on asbestosis, silicosis, chronic obstructive pulmonary disease, and asthma. Exposures known to cause dermatitis and cancer are reviewed. There is a discussion of engineered nanomaterials as a potential emerging hazard. Various approaches to prevention and control, including regulations and health services, are described.

scholarly journals Bronchiectasis and increased mortality in patients with corticosteroid-dependent severe asthma: a nationwide population study

2020 ◽  
Vol 14 ◽  
pp. 175346662096303
Author(s):  
Hayoung Choi ◽  
Hyun Lee ◽  
Jiin Ryu ◽  
Sung Jun Chung ◽  
Dong Won Park ◽  
...  
Keyword(s):  
Confidence Interval ◽  
Respiratory Diseases ◽  
Chronic Obstructive ◽  
Study Cohort ◽  
Limited Information ◽  
Term Survival ◽  
Obstructive Pulmonary Disease ◽  
All Cause Mortality ◽  
The Impact

Background: Long-term corticosteroid (CS) use is associated with increased mortality in patients with asthma, and comorbid bronchiectasis is also associated with frequent asthma exacerbation and increased healthcare use. However, there is limited information on whether bronchiectasis further increases mortality in patients with CS-dependent asthma. This study examined the impact of bronchiectasis on mortality in patients with CS-dependent asthma. Methods: A retrospective cohort of patients with CS-dependent asthma ⩾18 years old was established using records from the Korean National Health Insurance Service database from 2005 to 2015. Patients with CS-dependent asthma with and without bronchiectasis were matched by age, sex, type of insurance, and Charlson comorbidity index. We evaluated the hazard ratio (HR) for all-cause mortality in patients with bronchiectasis compared with those without bronchiectasis. Results: The study cohort included 754 patients with CS-dependent asthma with bronchiectasis and 3016 patients with CS-dependent asthma without bronchiectasis. Patients with CS-dependent asthma with bronchiectasis had a higher all-cause mortality than those without bronchiectasis (8429/100,000 versus 6962/100,000 person-years, p < 0.001). The adjusted HR for mortality in patients with CS-dependent asthma with bronchiectasis relative to those without bronchiectasis was 1.33 (95% confidence interval, 1.18–1.50), and the association was primarily significant for respiratory diseases (subdistribution HR = 1.65, 95% confidence interval, 1.42–1.92). Conclusions: Bronchiectasis further increases all-cause mortality in patients with CS-dependent asthma, a trend that was especially associated with respiratory diseases including chronic obstructive pulmonary disease. Strategies to improve treatment outcomes in patients with CS-dependent asthma with bronchiectasis are urgently needed to improve long-term survival. The reviews of this paper are available via the supplemental material section.

scholarly journals Exacerbations of COPD

2018 ◽  
Vol 27 (147) ◽  
pp. 170103 ◽  
Author(s):  
Christian Viniol ◽  
Claus F. Vogelmeier
Keyword(s):  
Viral Infections ◽  
Inhaled Corticosteroids ◽  
Current Knowledge ◽  
Pneumococcal Vaccination ◽  
Airflow Limitation ◽  
Chronic Obstructive ◽  
Copd Exacerbations ◽  
Recommended Treatment ◽  
Number Of Patients ◽  
The Impact

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. While COPD is a mainly chronic disease, a substantial number of patients suffer from exacerbations. Severe exacerbations are related to a significantly worse survival outcome. This review summarises the current knowledge on the different aspects of COPD exacerbations. The impact of risk factors and triggers such as smoking, severe airflow limitation, bronchiectasis, bacterial and viral infections and comorbidities is discussed. More severe exacerbations should be treated with β-agonists and anticholinergics as well as systemic corticosteroids. Antibiotic therapy should only be given to patients with presumed bacterial infection. Noninvasive ventilation is indicated in patients with respiratory failure. Smoking cessation is key to prevent further COPD exacerbations. Other aspects include choice of pharmacotherapy, including bronchodilators, inhaled corticosteroids, phosphodiesterase-4 inhibitors, long-term antibiotics and mucolytics. Better education and self-management as well as increased physical activity are important. Influenza and pneumococcal vaccination is recommended. Treatment of hypoxaemia and hypercapnia reduce the rate of COPD exacerbations, while most interventional bronchoscopic therapies increase exacerbation risk within the first months after the procedure.

scholarly journals The Impact of COVID-19 on Hospitalised COPD Exacerbations in Malta

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Yvette Farrugia ◽  
Bernard Paul Spiteri Meilak ◽  
Neil Grech ◽  
Rachelle Asciak ◽  
Liberato Camilleri ◽  
...  
Keyword(s):  
Length Of Hospital Stay ◽  
Chronic Obstructive ◽  
Inpatient Mortality ◽  
Obstructive Pulmonary Disease ◽  
Predictors Of Mortality ◽  
Copd Exacerbations ◽  
Number Of Patients ◽  
Significant Difference ◽  
The Difference ◽  
The Impact

Introduction and Aims. The first COVID-19 case in Malta was confirmed on the 7th of March 2020. This study is aimed at investigating a significant difference between the number of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) admissions and their inpatient outcome at Mater Dei Hospital during the COVID-19 pandemic when compared to the same period in 2019. Furthermore, we aim to determine predictors of mortality in AECOPD inpatients. Method. Data was collected retrospectively from electronic hospital records during the periods 1st March until 10th May in 2019 and 2020. Results. There was a marked decrease in AECOPD admissions in 2020, with a 54.2% drop in admissions ( n = 119 in 2020 vs. n = 259 in 2019). There was no significant difference in patient demographics or medical comorbidities. In 2020, there was a significantly lower number of patients with AECOPD who received nebulised medications during admission (60.4% in 2020 vs. 84.9% in 2019; p ≤ 0.001 ). There were also significantly lower numbers of AECOPD patients admitted in 2020 who received controlled oxygen via venturi masks (69.0% in 2020 vs. 84.5% in 2019; p = 0.006 ). There was a significant increase in inpatient mortality in 2020 (19.3% [ n = 23 ] and 8.4% [ n = 22 ] for 2020 and 2019, respectively, p = 0.003 ). Year was found to be the best predictor of mortality outcome ( p = 0.001 ). The lack of use of SABA pre-admission treatment ( p = 0.002 ), active malignancy ( p = 0.003 ), and increased length of hospital stay ( p = 0.046 ) were also found to be predictors of mortality for AECOPD patients; however, these parameters were unchanged between 2019 and 2020 and therefore could not account for the increase in mortality. Conclusions. There was a decrease in the number of admissions with AECOPD in 2020 during the COVID-19 pandemic, when compared to 2019. The year 2020 proved to be a significant predictor for inpatient mortality, with a significant increase in mortality in 2020. The decrease in nebuliser and controlled oxygen treatment noted in the study period did not prove to be a significant predictor of mortality when corrected for other variables. Therefore, the difference in mortality cannot be explained with certainty in this retrospective cohort study.

scholarly journals Effects of Air Pollutants on Airway Diseases

2021 ◽  
Vol 18 (18) ◽  
pp. 9905
Author(s):  
Yun-Gi Lee ◽  
Pureun-Haneul Lee ◽  
Seon-Muk Choi ◽  
Min-Hyeok An ◽  
An-Soo Jang
Keyword(s):  
Urban Areas ◽  
Air Pollutants ◽  
Respiratory Diseases ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Airway Diseases ◽  
Biological Contaminants ◽  
Underlying Mechanisms ◽  
The Impact

Air pollutants include toxic particles and gases emitted in large quantities from many different combustible materials. They also include particulate matter (PM) and ozone, and biological contaminants, such as viruses and bacteria, which can penetrate the human airway and reach the bloodstream, triggering airway inflammation, dysfunction, and fibrosis. Pollutants that accumulate in the lungs exacerbate symptoms of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Asthma, a heterogeneous disease with complex pathological mechanisms, is characterized by particular symptoms such as shortness of breath, a tight chest, coughing, and wheezing. Patients with COPD often experience exacerbations and worsening of symptoms, which may result in hospitalization and disease progression. PM varies in terms of composition, and can include solid and liquid particles of various sizes. PM concentrations are higher in urban areas. Ozone is one of the most toxic photochemical air pollutants. In general, air pollution decreases quality of life and life expectancy. It exacerbates acute and chronic respiratory symptoms in patients with chronic airway diseases, and increases the morbidity and risk of hospitalization associated with respiratory diseases. However, the mechanisms underlying these effects remain unclear. Therefore, we reviewed the impact of air pollutants on airway diseases such as asthma and COPD, focusing on their underlying mechanisms.

scholarly journals Exercise Training in Patients with Chronic Respiratory Diseases: Are Cardiovascular Comorbidities and Outcomes Taken into Account?—A Systematic Review

2019 ◽  
Vol 8 (9) ◽  
pp. 1458 ◽  
Author(s):  
Ana Machado ◽  
Kirsten Quadflieg ◽  
Ana Oliveira ◽  
Charly Keytsman ◽  
Alda Marques ◽  
...  
Keyword(s):  
Systematic Review ◽  
Heart Rate ◽  
Exercise Training ◽  
Respiratory Diseases ◽  
Cardiovascular Outcomes ◽  
Chronic Obstructive ◽  
Resting Heart Rate ◽  
Cardiovascular Comorbidities ◽  
Exercise Programmes ◽  
The Impact

Patients with chronic obstructive pulmonary disease (COPD), asthma and interstitial lung diseases (ILD) frequently suffer from cardiovascular comorbidities (CVC). Exercise training is a cornerstone intervention for the management of these conditions, however recommendations on tailoring programmes to patients suffering from respiratory diseases and CVC are scarce. This systematic review aimed to identify the eligibility criteria used to select patients with COPD, asthma or ILD and CVC to exercise programmes; assess the impact of exercise on cardiovascular outcomes; and identify how exercise programmes were tailored to CVC. PubMed, Scopus, Web of Science and Cochrane were searched. Three reviewers extracted the data and two reviewers independently assessed the quality of studies with the Quality Assessment Tool for Quantitative Studies. MetaXL 5.3 was used to calculate the individual and pooled effect sizes (ES). Most studies (58.9%) excluded patients with both stable and unstable CVC. In total, 26/42 studies reported cardiovascular outcomes. Resting heart rate was the most reported outcome measure (n = 13) and a small statistically significant effect (ES = −0.23) of exercise training on resting heart rate of patients with COPD was found. No specific adjustments to exercise prescription were described. Few studies have included patients with CVC. There was a lack of tailoring of exercise programmes and limited effects were found. Future studies should explore the effect of tailored exercise programmes on relevant outcome measures in respiratory patients with CVC.

Halotherapy in the rehabilitation of children in educational institutions

2020 ◽  
pp. 30-36
Author(s):  
Maya Khan ◽  
Irina Ivanova ◽  
Natalya Mikitchenko ◽  
Anna Dedurina ◽  
Natalya Lyan
Keyword(s):  
Respiratory Disease ◽  
Therapeutic Effect ◽  
Respiratory Diseases ◽  
Educational Institutions ◽  
Optimal Parameters ◽  
Acute Respiratory Disease ◽  
Acute Respiratory Diseases ◽  
Anti Inflammatory ◽  
The Impact

The aim of the study was to assess the impact of halotherapy performed in halocabinets on the health of children who often suffer from acute respiratory diseases. Based on the data obtained, the pronounced anti-inflammatory and sanogenetic effect of the factor was established, and the optimal parameters and halotherapy regimens were determined depending on the presence of symptoms of acute respiratory disease. Follow-up observations have confirmed the durability of the therapeutic effect.

scholarly journals New versus old guidelines for sarcopenia classification: What is the impact on prevalence and health outcomes?

2019 ◽  
Author(s):  
Fanny Petermann-Rocha ◽  
Minghao Chen ◽  
Stuart R Gray ◽  
Frederick K Ho ◽  
Jill P Pell ◽  
...  
Keyword(s):  
Health Outcomes ◽  
Respiratory Disease ◽  
Operational Definition ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Incidence And Mortality ◽  
European Working ◽  
All Cause Mortality ◽  
The Uk ◽  
The Impact

Abstract Introduction recently, the European Working Group on Sarcopenia in Older People (EWGSOP) established a new operational definition and cut-off points for sarcopenia. The aim of this study was, therefore, to compare the prevalence of sarcopenia and its associations with different health outcomes using the old (EWGSOP1) and new (EWGSOP2) definitions of sarcopenia in the UK Biobank cohort. Methods sarcopenia was defined as low grip strength plus low muscle mass. Using both EWGSOP cut-off points, we created specific sarcopenia variables. Prevalence of sarcopenia derived using both EWGSOP definitions was calculated and compared as well as prospective health outcomes including all-cause mortality as well as incidence and mortality from cardiovascular disease (CVD), respiratory disease and chronic obstructive pulmonary disease (COPD). Results the prevalence of sarcopenia based on the EWGSOP1 and EWGSOP2 classifications were 8.14 and 0.36%, respectively. Sarcopenia defined by EWGSOP1 was associated with a higher risk of respiratory disease and COPD as well as mortality from all-cause, CVD and respiratory diseases. However, only respiratory incidence remained associated with sarcopenia when EWGSOP2 was used (HR: 1.32 [95% CI: 1.05–1.66]). Moreover, although individuals classified as sarcopenic using both classifications had the highest risk of all-cause mortality and respiratory disease, those with sarcopenia based on EWGSOP1 only experienced a more extensive range of poorer health outcomes. Conclusion in comparison with EWGSOP1, the new classification (EWGSOP2) produced a lower estimate of sarcopenia prevalence and fewer associations with adverse health outcomes. Although these associations were higher, many become non-significant.

scholarly journals Relationships between prolonged physical and social isolation during the COVID-19 pandemic, reduced physical activity and disability in activities of daily living among people with advanced respiratory disease

2021 ◽  
Vol 18 ◽  
pp. 147997312110358
Author(s):  
Lucy Fettes ◽  
Joanne Bayly ◽  
Leonora Michelle de Bruin ◽  
Malini Patel ◽  
Stephen Ashford ◽  
...  
Keyword(s):  
Physical Activity ◽  
Activities Of Daily Living ◽  
Lung Disease ◽  
Respiratory Disease ◽  
Social Isolation ◽  
Daily Living ◽  
Daily Activities ◽  
World Health ◽  
Chronic Obstructive ◽  
The Impact

In people with advanced respiratory disease, we examined (i) the impact of COVID-19–related physical and social isolation on physical activity and (ii) relationships between time spent in isolation and disability in activities of daily living. Cross-sectional analysis was conducted in adults with advanced non-small cell lung cancer, chronic obstructive lung disease or interstitial lung disease. Measures included change in physical activity since physically and socially isolating (Likert scale) and disability (Barthel Index and Lawton–Brody IADL scale) or difficulty (World Health Organisation Disability Assessment Schedule-2.0) in daily activities. Multiple logistic regression was used to examine factors associated with disability in daily activities. 194/201 participants were isolating for a median [IQR] 5 [3–8]-month period, often leading to lower levels of physical activity at home ( n = 94, 47%), and outside home ( n = 129, 65%). 104 (52%) and 142 (71%) were not fully independent in basic and instrumental activities of daily living, respectively. 96% reported some degree of difficulty in undertaking daily activities. Prolonged physical and social isolation related to increased disability in basic (r = −0.28, p < 0.001) and instrumental (r = −0.24, p < 0.001) activities of daily living, and greater difficulty in daily activities (r = 0.22, p = 0.002). Each month spent in physical or social isolation was independently related to disability in basic activities of daily living (odds ratio [OR], 1.17 [95% CI: 1.03–1.33], p = 0.013). These findings suggest disability in daily activities is associated with prolonged physical or social isolation, which may present as difficulty in people who are fully independent. Post-isolation recovery and rehabilitation needs should be considered for all people deemed extremely clinically vulnerable.

scholarly journals Pulmonary Rehabilitation in Patients with Respiratory Disease

2014 ◽  
Vol 7 (1) ◽  
pp. 6-10
Author(s):  
Furqan Shoaib Siddiqi ◽  
Said Chaaban ◽  
Erin Petersen ◽  
K James Kallail ◽  
Mary Hope ◽  
...  
Keyword(s):  
Respiratory Disease ◽  
Pulmonary Rehabilitation ◽  
Respiratory Diseases ◽  
Respiratory Illness ◽  
Chronic Obstructive ◽  
Activity Levels ◽  
Chair Stand ◽  
Symptom Scores ◽  
St George's Respiratory Questionnaire ◽  
Minute Walk

Background. Limited evidence suggests that pulmonary rehabilitation be included in the management of restrictive lung diseases. The purpose of this study was to document pulmonary rehabilitation outcomes in patients with respiratory diseases other than chronic obstructive pulmonary disease (COPD). Methods. Clinical outcomes of 31patients with respiratory diseases other than COPD and 190 patients with COPD, seen over a 35-month period, were reviewed retrospectively. Patients were evaluated for a 6-minute walk, arm curl strength, chair stand strength, the St. George’s Respiratory Questionnaire (SGRQ) total score, SGRQ symptom scores, SGRQ activity levels, and SGRQ impact of respiratory illness on the patient’s life. Outcome measures were obtained before the start of pulmonary rehabilitation and after a minimum of nine therapy visits. Results. Pre- and post-rehabilitation changes in the 6-minute walk, arm curl strength, chair stand strength, the St. George’s Respiratory Questionnaire (SGRQ) total score, SGRQ symptom scores, SGRQ activity levels, and SGRQ impact scores improved significantly for both groups. However, non-COPD patients achieved significantly higher mean SGRQ impact scores and arm curl strength than patients with COPD. Conclusions. Pulmonary rehabilitation should be recommended for all patients with respiratory disease, not only those with COPD.

Sign in / Sign up

Export Citation Format

Share Document